Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Genetic diversity and host adaptation of avian H5N1 influenza viruses during human infection.

Welkers MRA, Pawestri HA, Fonville JM, Sampurno OD, Pater M, Holwerda M, Han AX, Russell CA, Jeeninga RE, Setiawaty V, de Jong MD, Eggink D.

Emerg Microbes Infect. 2019;8(1):262-271. doi: 10.1080/22221751.2019.1575700.

2.

ViroSpot microneutralization assay for antigenic characterization of human influenza viruses.

van Baalen CA, Jeeninga RE, Penders GH, van Gent B, van Beek R, Koopmans MP, Rimmelzwaan GF.

Vaccine. 2017 Jan 3;35(1):46-52. doi: 10.1016/j.vaccine.2016.11.060. Epub 2016 Nov 26.

3.

Dendritic cell type-specific HIV-1 activation in effector T cells: implications for latent HIV-1 reservoir establishment.

van der Sluis RM, van Capel TM, Speijer D, Sanders RW, Berkhout B, de Jong EC, Jeeninga RE, van Montfort T.

AIDS. 2015 Jun 1;29(9):1003-14. doi: 10.1097/QAD.0000000000000637.

PMID:
25768834
4.

Improved detection of artifactual viral minority variants in high-throughput sequencing data.

Welkers MR, Jonges M, Jeeninga RE, Koopmans MP, de Jong MD.

Front Microbiol. 2015 Jan 22;5:804. doi: 10.3389/fmicb.2014.00804. eCollection 2014.

5.

Candidate prioritization for low-abundant differentially expressed proteins in 2D-DIGE datasets.

Nandal UK, Vlietstra WJ, Byrman C, Jeeninga RE, Ringrose JH, van Kampen AH, Speijer D, Moerland PD.

BMC Bioinformatics. 2015 Jan 28;16:25. doi: 10.1186/s12859-015-0455-x.

6.

Culturing of respiratory viruses in well-differentiated pseudostratified human airway epithelium as a tool to detect unknown viruses.

Farsani SM, Deijs M, Dijkman R, Molenkamp R, Jeeninga RE, Ieven M, Goossens H, van der Hoek L.

Influenza Other Respir Viruses. 2015 Jan;9(1):51-7. doi: 10.1111/irv.12297. Epub 2014 Dec 8.

7.

Interplay between viral Tat protein and c-Jun transcription factor in controlling LTR promoter activity in different human immunodeficiency virus type I subtypes.

van der Sluis RM, Derking R, Breidel S, Speijer D, Berkhout B, Jeeninga RE.

J Gen Virol. 2014 Apr;95(Pt 4):968-79. doi: 10.1099/vir.0.059642-0. Epub 2014 Jan 21.

PMID:
24447950
8.

Emergence of the virulence-associated PB2 E627K substitution in a fatal human case of highly pathogenic avian influenza virus A(H7N7) infection as determined by Illumina ultra-deep sequencing.

Jonges M, Welkers MR, Jeeninga RE, Meijer A, Schneeberger P, Fouchier RA, de Jong MD, Koopmans M.

J Virol. 2014 Feb;88(3):1694-702. doi: 10.1128/JVI.02044-13. Epub 2013 Nov 20.

9.

Subclinical avian influenza A(H5N1) virus infection in human, Vietnam.

Le MQ, Horby P, Fox A, Nguyen HT, Le Nguyen HK, Hoang PM, Nguyen KC, de Jong MD, Jeeninga RE, Rogier van Doorn H, Farrar J, Wertheim HF.

Emerg Infect Dis. 2013 Oct;19(10):1674-7. doi: 10.3201/eid1910.130730.

10.

Establishment and molecular mechanisms of HIV-1 latency in T cells.

van der Sluis RM, Jeeninga RE, Berkhout B.

Curr Opin Virol. 2013 Dec;3(6):700-6. doi: 10.1016/j.coviro.2013.07.006. Epub 2013 Aug 13. Review.

PMID:
23953324
11.

Identification of a new cyclovirus in cerebrospinal fluid of patients with acute central nervous system infections.

Tan le V, van Doorn HR, Nghia HD, Chau TT, Tu le TP, de Vries M, Canuti M, Deijs M, Jebbink MF, Baker S, Bryant JE, Tham NT, BKrong NT, Boni MF, Loi TQ, Phuong le T, Verhoeven JT, Crusat M, Jeeninga RE, Schultsz C, Chau NV, Hien TT, van der Hoek L, Farrar J, de Jong MD.

MBio. 2013 Jun 18;4(3):e00231-13. doi: 10.1128/mBio.00231-13.

12.

Dendritic cell-induced activation of latent HIV-1 provirus in actively proliferating primary T lymphocytes.

van der Sluis RM, van Montfort T, Pollakis G, Sanders RW, Speijer D, Berkhout B, Jeeninga RE.

PLoS Pathog. 2013 Mar;9(3):e1003259. doi: 10.1371/journal.ppat.1003259. Epub 2013 Mar 21.

13.

An AP-1 binding site in the enhancer/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection.

Duverger A, Wolschendorf F, Zhang M, Wagner F, Hatcher B, Jones J, Cron RQ, van der Sluis RM, Jeeninga RE, Berkhout B, Kutsch O.

J Virol. 2013 Feb;87(4):2264-77. doi: 10.1128/JVI.01594-12. Epub 2012 Dec 12.

14.

Quantitation of HIV-1 DNA with a sensitive TaqMan assay that has broad subtype specificity.

van der Sluis RM, van Montfort T, Centlivre M, Schopman NC, Cornelissen M, Sanders RW, Berkhout B, Jeeninga RE, Paxton WA, Pollakis G.

J Virol Methods. 2013 Jan;187(1):94-102. doi: 10.1016/j.jviromet.2012.09.019. Epub 2012 Oct 8.

PMID:
23059551
15.

Proteomic analysis of HIV-T cell interaction: an update.

Kramer G, Moerland PD, Jeeninga RE, Vlietstra WJ, Ringrose JH, Byrman C, Berkhout B, Speijer D.

Front Microbiol. 2012 Jul 4;3:240. doi: 10.3389/fmicb.2012.00240. eCollection 2012.

16.

Inhibition of HIV-1 replication with stable RNAi-mediated knockdown of autophagy factors.

Eekels JJ, Sagnier S, Geerts D, Jeeninga RE, Biard-Piechaczyk M, Berkhout B.

Virol J. 2012 Mar 16;9:69. doi: 10.1186/1743-422X-9-69.

17.

A competitive cell growth assay for the detection of subtle effects of gene transduction on cell proliferation.

Eekels JJ, Pasternak AO, Schut AM, Geerts D, Jeeninga RE, Berkhout B.

Gene Ther. 2012 Nov;19(11):1058-64. doi: 10.1038/gt.2011.191. Epub 2011 Nov 24.

PMID:
22113311
18.

Latency profiles of full length HIV-1 molecular clone variants with a subtype specific promoter.

van der Sluis RM, Pollakis G, van Gerven ML, Berkhout B, Jeeninga RE.

Retrovirology. 2011 Sep 16;8:73. doi: 10.1186/1742-4690-8-73.

19.

Long-term inhibition of HIV-1 replication with RNA interference against cellular co-factors.

Eekels JJ, Geerts D, Jeeninga RE, Berkhout B.

Antiviral Res. 2011 Jan;89(1):43-53. doi: 10.1016/j.antiviral.2010.11.005. Epub 2010 Nov 18.

PMID:
21093490
20.

Possible applications for replicating HIV 1 vectors.

Das AT, Jeeninga RE, Berkhout B.

HIV Ther. 2010 May 1;4(3):361-369.

21.

The new influenza A (H1N1) pandemic.

Jeeninga RE, de Jong MD, Berkhout B.

J Formos Med Assoc. 2009 Jul;108(7):523-5. No abstract available.

22.

HIV-1 latency in actively dividing human T cell lines.

Jeeninga RE, Westerhout EM, van Gerven ML, Berkhout B.

Retrovirology. 2008 Apr 25;5:37. doi: 10.1186/1742-4690-5-37.

23.

Proteomic studies reveal coordinated changes in T-cell expression patterns upon infection with human immunodeficiency virus type 1.

Ringrose JH, Jeeninga RE, Berkhout B, Speijer D.

J Virol. 2008 May;82(9):4320-30. doi: 10.1128/JVI.01819-07. Epub 2008 Feb 20.

24.

Characterization of an HIV-1 group M variant that is distinct from the known subtypes.

van der Hoek L, Pollakis G, Lukashov VV, Jebbink MF, Jeeninga RE, Bakker M, Dukers N, Jurriaans S, Paxton WA, Back NK, Berkhout B.

AIDS Res Hum Retroviruses. 2007 Mar;23(3):466-70.

PMID:
17411380
25.

Heterogeneity of signal transducer and activator of transcription binding sites in the long-terminal repeats of distinct HIV-1 subtypes.

Crotti A, Chiara GD, Ghezzi S, Lupo R, Jeeninga RE, Liboi E, Lievens PM, Vicenzi E, Bovolenta C, Berkhout B, Poli G.

Open Virol J. 2007;1:26-32. doi: 10.2174/1874357900701010026. Epub 2007 Oct 20.

26.
27.

Pertussis toxin B-oligomer suppresses IL-6 induced HIV-1 and chemokine expression in chronically infected U1 cells via inhibition of activator protein 1.

Rizzi C, Crippa MP, Jeeninga RE, Berkhout B, Blasi F, Poli G, Alfano M.

J Immunol. 2006 Jan 15;176(2):999-1006.

28.

Construction of a minimal HIV-1 variant that selectively replicates in leukemic derived T-cell lines: towards a new virotherapy approach.

Jeeninga RE, Jan B, van der Linden B, van den Berg H, Berkhout B.

Cancer Res. 2005 Apr 15;65(8):3347-55.

29.
30.

Human immunodeficiency virus type 1 subtypes have a distinct long terminal repeat that determines the replication rate in a host-cell-specific manner.

van Opijnen T, Jeeninga RE, Boerlijst MC, Pollakis GP, Zetterberg V, Salminen M, Berkhout B.

J Virol. 2004 Apr;78(7):3675-83.

31.
32.

Identification of cis-acting elements involved in 3'-end formation of Saccharomyces cerevisiae 18S rRNA.

van Beekvelt CA, Jeeninga RE, van't Riet J, Venema J, Raué HA.

RNA. 2001 Jun;7(6):896-903.

33.

Evolution of AZT resistance in HIV-1: the 41-70 intermediate that is not observed in vivo has a replication defect.

Jeeninga RE, Keulen W, Boucher C, Sanders RW, Berkhout B.

Virology. 2001 May 10;283(2):294-305.

34.

Functional differences between the long terminal repeat transcriptional promoters of human immunodeficiency virus type 1 subtypes A through G.

Jeeninga RE, Hoogenkamp M, Armand-Ugon M, de Baar M, Verhoef K, Berkhout B.

J Virol. 2000 Apr;74(8):3740-51.

35.

The effect of template RNA structure on elongation by HIV-1 reverse transcriptase.

Klasens BI, Huthoff HT, Das AT, Jeeninga RE, Berkhout B.

Biochim Biophys Acta. 1999 Mar 19;1444(3):355-70.

PMID:
10095059
36.

The mechanism of actinomycin D-mediated inhibition of HIV-1 reverse transcription.

Jeeninga RE, Huthoff HT, Gultyaev AP, Berkhout B.

Nucleic Acids Res. 1998 Dec 1;26(23):5472-9.

37.

Variable regions V13 and V3 of Saccharomyces cerevisiae contain structural features essential for normal biogenesis and stability of 5.8S and 25S rRNA.

Jeeninga RE, Van Delft Y, de Graaff-Vincent M, Dirks-Mulder A, Venema J, Raué HA.

RNA. 1997 May;3(5):476-88.

38.

Acetylation of ribosomal protein S5 affected by defects in the central pseudoknot in 16S ribosomal RNA?

Poot RA, Jeeninga RE, Pleij CW, van Duin J.

FEBS Lett. 1997 Jan 20;401(2-3):175-9.

39.
40.

Organization and nucleotide sequences of two lactococcal bacteriocin operons.

van Belkum MJ, Hayema BJ, Jeeninga RE, Kok J, Venema G.

Appl Environ Microbiol. 1991 Feb;57(2):492-8.

Supplemental Content

Loading ...
Support Center